Bank Hapoalim BM’s UroGen Pharma URGN Stock Holding History

Bank Hapoalim BM’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-14,450	Closed	-$281K	–	248
2021 Q1	$281K	Sell	14,450 -15,570	-52%	-$331K	0.04%	202
2020 Q4	$541K	Buy	+30,020	New	+$629K	0.07%	141
2020 Q3	–	Sell	-14,831	Closed	-$387K	–	196
2020 Q2	$387K	Buy	14,831 +350	+2%	+$8.55K	0.09%	131
2020 Q1	$258K	Sell	14,481 -2,574	-15%	-$69.5K	0.08%	143
2019 Q4	$569K	Sell	17,055 -10,175	-37%	-$278K	0.12%	103
2019 Q3	$653K	Buy	27,230 +1,260	+5%	+$41.2K	0.16%	87
2019 Q2	$933K	Buy	25,970 +1,845	+8%	+$68K	0.23%	73
2019 Q1	$891K	Buy	+24,125	New	+$1.01M	0.21%	76
2018 Q4	–	Sell	-4,670	Closed	-$221K	–	193
2018 Q3	$221K	Sell	4,670 -62,455	-93%	-$2.9M	0.05%	171
2018 Q2	$3.34M	Buy	67,125 +14,825	+28%	+$863K	0.91%	32
2018 Q1	$2.6M	Buy	+52,300	New	+$2.62M	0.67%	37

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

HCM

Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank Hapoalim BM's URGN Position: Q2 2021 in Review

Bank Hapoalim BM sold out of UroGen Pharma (URGN) in Q2 2021, closing a stake of 14,450 shares — an estimated $281K sold.

Bank Hapoalim BM first reported a position in URGN in Q1 2018 and held it in 11 quarters. The position peaked at $3.34M in Q2 2018. 82 funds tracked by Wall St. Rank hold URGN as of Q2 2021.

Bank Hapoalim BM reported no remaining UroGen Pharma position as of Q2 2021 after selling out during the quarter.
Bank Hapoalim BM sold 14,450 UroGen Pharma shares in Q2 2021, an estimated $281K.
Bank Hapoalim BM first reported a position in UroGen Pharma in Q1 2018 and held it in 11 quarters.
Bank Hapoalim BM's UroGen Pharma position peaked at $3.34M in Q2 2018.
82 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2021.

Based on Bank Hapoalim BM's 13F filing for Q2 2021, filed 5 Aug 2021.